Search results for " protocol"

showing 10 items of 1320 documents

Sustained telomere erosion due to increased stem cell turnover during triple autologous hematopoietic stem cell transplantation.

2007

Telomeres cap chromosomal ends and are shortened throughout a lifetime. Additional telomere erosion has been documented during conventional chemotherapy or hematopoietic stem cell transplantation. Previous studies of stem cell transplantation reported variable amounts of telomere shortening with inconsistent results regarding the persistence of telomere shortening. Here we have prospectively studied telomere length and proliferation kinetics of hematopoietic cells in aggressive non-Hodgkin lymphoma patients who underwent a four-course high-dose chemotherapy protocol combined with triple autologous stem cell transplantation. We observed sustained telomere shortening in hematopoietic cells af…

MaleCancer ResearchTransplantation Conditioningmedicine.medical_treatmentHematopoietic stem cell transplantationAntibodies Monoclonal Murine-DerivedAutologous stem-cell transplantationAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorLymphocytesProspective StudiesCellular SenescenceEtoposideMyelopoiesisLymphoma Non-HodgkinAntibodies MonoclonalHematologyMiddle AgedTelomereCombined Modality TherapyHaematopoiesisVincristineFemaleStem cellRituximabCell DivisionPrednisoloneTransplantation AutologousDrug Administration ScheduleGeneticsmedicineHumansMolecular BiologyCyclophosphamideChemotherapyPeripheral Blood Stem Cell Transplantationbusiness.industryCell BiologyMyeloablative Agonistsmedicine.diseaseHematopoietic Stem CellsTelomereLymphomaTransplantationClinical Trials Phase III as TopicDoxorubicinImmunologyCancer researchbusinessGranulocytesExperimental hematology
researchProduct

Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International society of paediatric oncology (SI…

1995

In a multicentre randomised clinical trial 364 children with biopsy proven medulloblastoma were randomly assigned to receive or not pre-radiotherapy chemotherapy. Children with total or subtotal removal of the tumour, no evidence of invasive brain stem involvement, and no evidence of metastatic disease either within or without the cranium were designated "low risk", those with gross residual tumour, evidence of invasive brain stem involvement or metastases in the central nervous system were designated "high risk". All children were prescribed 55 Gy to the tumour bearing area. "Low risk" children could be randomised to "standard" radiotherapy 35 Gy to the craniospinal axis or "reduced" dose …

MaleCancer ResearchVincristinemedicine.medical_specialtyPediatricsTime FactorsAdolescentmedicine.medical_treatmentProcarbazinelaw.inventionRandomized controlled trialRecurrenceRisk FactorslawAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineProspective StudiesCerebellar NeoplasmsChildProspective cohort studyMedulloblastomabusiness.industryInfantRadiotherapy Dosagemedicine.diseaseCombined Modality TherapySurvival AnalysisSurgeryRadiation therapyClinical trialOncologyChild PreschoolPediatrics Perinatology and Child HealthFemalebusinessCraniospinalMedulloblastomamedicine.drugMedical and Pediatric Oncology
researchProduct

Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform

2019

Background/Aim: The Philadelphia chromosome is the most frequent cytogenetic abnormality in chronic myelogenous (CML). More than 95% of CML patients are diagnosed with the e13a2 or e14a2 BCR-ABL1 fusion transcripts while, in about 1% of these individuals, the break generates the e1a2 rearrangement. Furthermore, about 5% of CML patients are diagnosed with rare BCR-ABL1 fusion transcripts, such as e19a2, e8a2, e13a3, e14a3, e1a3 and e6a2. However, there is limited evidence concerning the clinical and prognostic implications of these infrequent oncogenic variants for CML patients receiving tyrosine kinase inhibitors (TKIs). Case Report: We describe a novel atypical e12a2 insertion/deletion (In…

MaleCancer Researchbcr-ablFusion Proteins bcr-ablBCR-ABL1; CML; E12a2; E13a2; Nilotinib; Ponatinib; TKIs; Antineoplastic Combined Chemotherapy Protocols; Fusion Proteins bcr-abl; Humans; INDEL Mutation; Imidazoles; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Protein Isoforms; Pyridazines; Pyrimidines; Treatment Outcomechemistry.chemical_compoundExon0302 clinical medicineINDEL Mutationhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsProtein IsoformsChronicCMLLeukemiaPonatinibImidazolesGeneral MedicineMiddle AgedTKIPyridazinesTreatment OutcomeOncology030220 oncology & carcinogenesisPonatinibPyridazineTyrosine kinaseINDEL MutationE13a2Humanmedicine.drugPhiladelphia chromosome03 medical and health sciencesMyelogenousLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansImidazoleAntineoplastic Combined Chemotherapy Protocolbusiness.industryBreakpointProtein IsoformFusion Proteinsmedicine.diseaseNilotinibBCR-ABL1PyrimidinesPyrimidinechemistryNilotinibTKIsCancer researchBCR-ABL PositivebusinessE12a2Myelogenous
researchProduct

Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA a…

2019

Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a complex karyotype (CK) is yet to be clarified. We aimed to investigate the relationship of CK with relapse incidence in 1559 consecutive APL patients enrolled in three consecutive trials. Treatment consisted of AIDA induction followed by risk-adapted consolidation. A CK (CK) was defined as the presence of ≥2 ACA, and a very CK (CK+) as ≥3 ACA. Eighty-nine patients (8%) had a CK, of whom 41 (4%) had CK+. The 5-year cumulative incidence of relapse (CIR) in patients with CK was 18%, and 12% in those with <2 ACA (p=.09). Among patients wi…

MaleCancer Researchcomplex karyotypeANTHRACYCLINE MONOCHEMOTHERAPYmedicine.medical_treatmentAbnormal KaryotypechemotherapyGastroenterologyLeukocyte Count0302 clinical medicineLeukemia Promyelocytic AcuteRecurrenceAcute promyelocytic leukemiaAntineoplastic Combined Chemotherapy ProtocolsPROGNOSTIC-SIGNIFICANCECumulative incidenceATRAChildIn Situ Hybridization FluorescenceAged 80 and overrelapsePETHEMAIncidence (epidemiology)ADDITIONAL CHROMOSOME-ABNORMALITIESAge FactorsHematologyMiddle AgedPrognosisARSENIC TRIOXIDEFLT3 MUTATIONSLeukemiaTreatment OutcomeOncologyChild Preschool030220 oncology & carcinogenesisCytogenetic AnalysisFemaleAdultAcute promyelocytic leukemiamedicine.medical_specialtyCYTOGENETIC CHANGESAdolescentYoung Adult03 medical and health sciencesInternal medicineStatistical significanceComplex KaryotypemedicineHumansClinical significanceAgedCONSOLIDATION THERAPYChromosome AberrationsChemotherapybusiness.industrymedicine.diseaseRISK-ADAPTED TREATMENTTRANS-RETINOIC ACIDATRA Acute promyelocytic leukemia chemotherapy complex karyotype prognostic relapsebusinessprognostic030215 immunologyLeukemia & Lymphoma
researchProduct

Colorectal cancer stage at diagnosis in migrants versus non-migrants (KoMigra) : study protocol of a cross-sectional study in Germany

2014

Background: In Germany, about 20% of the total population have a migration background. Differences exist between migrants and non-migrants in terms of health care access and utilisation. Colorectal cancer is the second most common malignant tumour in Germany, and incidence, staging and survival chances depend, amongst other things, on ethnicity and lifestyle. The current study investigates whether stage at diagnosis differs between migrants and non-migrants with colorectal cancer in an area of high migration and attempts to identify factors that can explain any differences. Methods/Design: Data on tumour and migration status will be collected for 1,200 consecutive patients that have receive…

MaleCancer Researchmedicine.medical_specialtyCross-sectional studyLogistic regressionMigrantsHealth Services AccessibilityStudy ProtocolCross-sectionalGermanySurveys and QuestionnairesObservational studyHealth careEthnicityGeneticsHumansMedicineProspective Studiesddc:610Hard-to-reach populationProspective cohort studySocioeconomic statusAgedNeoplasm StagingTransients and MigrantsGynecologybusiness.industryOdds ratioMiddle AgedColorectal cancerCross-Sectional StudiesOncologyHealth care accessHard-to-reach population ; Ethnicity ; Observational study ; Migrants ; Colorectal cancer ; Health care access ; Cross-sectionalFemaleObservational studyOrdered logitColorectal NeoplasmsbusinessDemography
researchProduct

Acute and chronic hepatitis in childhood leukemia: a multicentric study from the Italian Pediatric Cooperative Group for Therapy of Acute Leukemia (A…

1985

The incidence of acute and chronic liver damage and its relation to hepatitis B virus (HBV) infection was evaluated in 164 consecutive children with acute leukemia seen in ten Italian hemato-pediatric units. Thirteen out of 164 children (7.9%) had acute hepatitis (AH) during treatment, while 8/90 (8.8%) showed an acute exacerbation of liver damage within 6 months after therapy withdrawal. Seven of the 13 children with AH while on therapy were HBsAg positive. In 12/13 cases, liver disease progressed to chronicity. Five of eight children who developed AH after completion of treatment were HBsAg positive. Eighty-nine patients (54.2%) developed biochemical evidence of chronic hepatitis during t…

MaleCancer Researchmedicine.medical_specialtyHBsAgChildhood leukemiaExacerbationAdolescentmedicine.disease_causeGastroenterologyacute hepatitisHepatitisLiver diseasechronic hepatitiLiver Function TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChildHepatitis B virusAcute leukemiaHepatitis B Surface AntigensLeukemiabusiness.industryLiver cellacute hepatitichildhood leukemiavirus diseasesInfantmedicine.diseaseacute hepatitis; chronic hepatitis; childhood leukemiaHepatitis BLeukemia LymphoidLeukemiaAcute and chronic hepatitis; childhood leukemia; multicentric study from AIEOPOncologyItalyChild PreschoolPediatrics Perinatology and Child HealthImmunologyAcute DiseaseFemalechronic hepatitisChemical and Drug Induced Liver InjurybusinessMedical and pediatric oncology
researchProduct

Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung ca…

2005

Purpose To study the prognostic value for overall survival of baseline assessment of functional status, comorbidity, and quality of life (QoL) in elderly patients with advanced non—small-cell lung cancer treated with chemotherapy. Patients and Methods Data from 566 patients enrolled onto the phase III randomized Multicenter Italian Lung Cancer in the Elderly Study (MILES) study were analyzed. Functional status was measured as activities of daily living (ADL) and instrumental ADL (IADL). The presence of comorbidity was assessed with a checklist of 33 items; items 29 and 30 of the European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 (EORTC QLQ-C30) wer…

MaleCancer Researchmedicine.medical_specialtyLung NeoplasmsActivities of daily livingHealth StatuscarcinomaVinblastineVinorelbineDeoxycytidineolder peopleQuality of lifeInstrumental activitieCarcinoma Non-Small-Cell LungInternal medicineActivities of Daily LivingAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerAgedAged 80 and overvalidationProportional hazards modelbusiness.industryQLQ-C30Age FactorsCancerVinorelbineclinical trialPrognosismedicine.diseaseGemcitabineComorbidityhumanitiescomorbidityOncologyQuartileQuality of LifePhysical therapyimpactGeriatric oncologyFemalebusinessRandomized-trialmedicine.drug
researchProduct

High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma.

2000

BACKGROUND The lungs are a frequent site of metastasis in patients with melanoma, and this may cause respiratory problems in the terminal phase of the illness. Inhalation interleukin (IL)-2 therapy to the lung has been piloted and appears to be well tolerated. METHODS Twenty-seven patients were treated with single agent dacarbazine and concurrent high dose inhalation IL-2 36 million IU per day). The patients previously had progressed on chemotherapy, predominately dacarbazine-based regimens. Patients included those with American Joint Committee on Cancer Stage IV melanoma, predominately those with lung metastases, but patients with extrapulmonary metastases also were allowed on the study. R…

MaleCancer Researchmedicine.medical_specialtyLung NeoplasmsDacarbazinemedicine.medical_treatmentAntineoplastic AgentsGastroenterologyMetastasisInternal medicineCause of DeathAdministration InhalationAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAntineoplastic Agents AlkylatingMelanomaChemotherapyInhalationbusiness.industryMelanomaRespiratory diseaseRemission InductionCancerReproducibility of ResultsConfounding Factors Epidemiologicmedicine.diseaseRecombinant ProteinsSurgeryDacarbazineTreatment OutcomeOncologyConcomitantDisease ProgressionInterleukin-2FemaleSafetybusinessmedicine.drugFollow-Up StudiesCancer
researchProduct

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)

2017

Leukemia : normal and malignant hemopoiesis 31(4), 846-852 (2017). doi:10.1038/leu.2016.334

MaleCancer Researchmedicine.medical_specialtyLymphomaPopulationMedizinProcarbazineGastroenterologyCentral Nervous System Neoplasms03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansImmunologic FactorseducationAgedNeoplasm StagingProportional Hazards ModelsAged 80 and overeducation.field_of_studyHematologybusiness.industryRemission InductionPrimary central nervous system lymphomaHematologyLomustinemedicine.diseaseSurgeryTumor BurdenMethotrexateTreatment OutcomeOncology030220 oncology & carcinogenesisCytarabineQuality of LifeMethotrexateRituximabOriginal ArticleFemalebusiness030215 immunologymedicine.drugLeukemia
researchProduct

High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck

1992

A group of 60 patients with advanced head/neck cancer were treated with high-dose folinic acid (500 mg/m-2/week-1) plus 5-fluorouracil (400 mg/m-2/week-1 on day 1, and cisplatin (20 mg/m-2/week-1) 24 h after folinic acid infusion was completed. Out of 55 evaluable patients, 10 patients (18%) experienced a complete response with a mean duration of 11.4+ months, 25 patients had a partial response (45%) of 6.7+ months, 6 patients (11%) showed a stabilization of 4.8+ months, and 14 (25%) progressed. The overall response rate was 63.6% (95% confidence limits 56.5%-69.5%). Patients pretreated with radiotherapy had a 67% overall response rate, while those pretreated with chemotherapy showed a 54% …

MaleCancer Researchmedicine.medical_specialtyNauseamedicine.medical_treatmentCystadenocarcinomaLeucovorinAdenocarcinomaGastroenterologyDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisChemotherapyLeukopeniabusiness.industryCarcinomaCancerGeneral MedicineMiddle Agedmedicine.diseaseRadiation therapyOncologyHead and Neck NeoplasmsFluorouracilAnesthesiaCarcinoma Squamous CellVomitingFemaleFluorouracilCisplatinmedicine.symptombusinessmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct